Table 2 Cost savings associated with implementation of the sFlt-1/PlGF ratio in the base case and sensitivity scenario analyses

From: Economic evaluation of the sFlt-1/PlGF ratio for the short-term prediction of preeclampsia in a Japanese cohort of the PROGNOSIS Asia study

Scenario

Hospitalization rate without sFlt-1/PlGF ratio, %

Cost per sFlt-1/PlGF ratio test, JPY

sFlt-1/PlGF ratio retest option

Hospitalization rate with sFlt-1/PlGF ratio result ≤38, %

Hospitalization rate with sFlt-1/PlGF ratio result >38, %

Cost saving per patient, JPY

Base case (including NICU admission for RDS)

14.4

9000

No

0.56

40

16,373

Hospitalization rate without sFlt-1/PlGF ratio increased to overall rate in PROGNOSIS Asia

26.9

9000

No

0.56

40

69,482

sFlt-1/PlGF ratio cost per test reduced by 20%

14.4

7200

No

0.56

40

18,173

sFlt-1/PlGF ratio cost per test increased by 20%

14.4

10,800

No

0.56

40

14,573

sFlt-1/PlGF ratio retest considered for every woman

14.4

9000

Yes

0.56

40

7373

Hospitalization rate with sFlt-1/PlGF ratio ≤38 increased to 4%

14.4

9000

No

4

40

6782

Hospitalization rate with sFlt-1/PlGF ratio ≤38 reduced to 0%

14.4

9000

No

0

40

17,934

Hospitalization rate with sFlt-1/PlGF ratio >38 increased to 50%

14.4

9000

No

0.56

50

9157

  1. JPY Japanese yen, NICU neonatal intensive care unit, PlGF placental growth factor, RDS respiratory distress syndrome, sFlt-1 soluble fms-like tyrosine kinase-1
Back to article page